Skip to main content

Industry News

  • Nanoscope Therapeutics Receives Fast Track Designation by the FDA for MCO-010 for the Treatment of Retinitis Pigmentosa

    Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to MCO-010, an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic monotherapy to restore vision in blind patients, for the treatment of retinitis pigmentosa (RP) via intravitreal injection.

  • Panacea Biotech gets order of USD 127.30 million from UNICEF & PAHO for pentavalent vaccine

    Panacea Biotec, one of India's leading biotechnology companies, has received long-term supply awards worth USD 127.30 million (around INR 1,040 Crore) from UNICEF and Pan American Health Organization (PAHO) for supply of its WHO pre-qualified fully liquid Pentavalent vaccine, Easyfive-TT'" (DTwP-HepB-Hib).

  • Pfizer Completes Acquisition of Global Blood Therapeutics

    Pfizer Inc announced the completion of its acquisition of Global Blood Therapeutics, Inc. (GBT), a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities starting with sickle cell disease (SCD). The acquisition reinforces Pfizer’s commitment to SCD, building on a 30-year legacy in the rare hematology space.

  • Controversial syrup was only sent to Gambia, says Regulators

    It has come to notice that controversial syrups exported by India based Maiden Pharmaceutical are linked to the death of 66 children in Gambia. Regulators informed that the company has manufactured and exported these products only to Gambia.

  • Lilly receives U.S. FDA Fast Track designation for tirzepatide

    Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities. The FDA grants Fast Track designation to facilitate the development and expedite the review of medicines to treat serious conditions and fill an unmet medical need. Fast Track designation is intended to bring promising medicines to patients sooner.

  • Merck invests USD 500 mn in Singapore to develop manufacturing plant

    MSD announced the opening of a new secondary packaging facility to support the production of vaccines and biologics, including the company’s cancer immunotherapy products. MSD also broke ground for a new inhaler production facility for the manufacture of new generation inhaler medicines in Singapore.

  • Glenmark becomes the First Pharmaceutical Company to launch Lobeglitazone in India for Uncontrolled Type 2 Diabetes in Adults

    Glenmark Pharmaceuticals Limited an innovation‐driven global pharmaceutical company, became the first to launch Thiazolidinedione Lobeglitazone (Lobeglitazone) in India for the treatment of type 2 diabetes in adults. Marketed under the brand name LOBG; it contains Lobeglitazone (0.5 mg) and to be taken once daily under prescription to improve glycemic control in adult diabetic patients.

  • WHO alerts against Maiden Pharmaceuticals cough syrups after 66 children died in Gambia

    World Health Organization (WHO) alerts against Indian made cough syrups after 66 children died in Gambia. The four medicines are cough and cold syrups produced by Maiden Pharmaceuticals Limited, in India. WHO is conducting further investigation with the company and regulatory authorities in India.

    The four products are Promethazine Oral Solution, Kofexmalin Baby Cough Syrup, Makoff Baby Cough Syrup and Magrip N Cold Syrup.

  • Lupin gets EIR from USFDA for its Ankleshwar plant

    Lupin Limited has received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (US FDA) for its Ankleshwar manufacturing facility, located in Gujarat, India.

    The inspection of the facility was conducted from August 16-19, 2022 by USFDA. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions. The company invested 9.6% of its revenue on research and development in FY21.

  • Lupin Receives Approval from USFDA for Darunavir Tablets

    Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

Subscribe to Industry News